Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

16.57 -0.02 (-0.12%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
24 25 Next >
Teva Launches New “Pivot to Growth” Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Benzinga 
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last... 
Via Benzinga
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
The U.S. 
Via Benzinga
Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales
Teva reported absolutely flat sales in the first quarter and light earnings. 
Via Investor's Business Daily
Teva Pharmaceutical Clocks Lower Profits On Flat Q1 Sales, Sticks To Annual Guidance
Via Benzinga
Teva Pharmaceutical Indus: Q1 Earnings Insights
Via Benzinga
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
TEVA earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
FDA Approves Teva/MedinCell's Antipsychotic Injection For Adult Schizophrenia Patients
Via Benzinga
Nasdaq, S&amp;P 500 Futures Slip Ahead Of Inflation Data — But Analyst Hints It Still Might Be Ok To Be Bullish
Via Benzinga
Disney, Occidental Petroleum And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Investor Sentiment Improves Slightly Ahead Of Key Inflation Reports
The CNN Money Fear and Greed index showed slight improvement in overall sentiment among U.S. investors on Tuesday. 
Via Benzinga
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
From Teva Pharmaceutical Industries Limited
Via Business Wire
Busy Week Ahead As Volatility Gauges Flash Red
With CPI data being released on Wednesday and the Biden administration starting talks with Congress on Tuesday, it looks like this could be a big week for volatility. 
Via Talk Markets
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Launch New Growth Strategy at Investor Day
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
1 "Safe" Stock to Avoid and 1 to Consider Buying in April
There's more to the concept of safety than having a business model that looks safe. 
Via The Motley Fool
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday. 
Via Benzinga
Boeing, Spirit AeroSystems And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Complete Response Letter Received for AVT02 Biologics License Application
From Teva Pharmaceutical Industries Limited
Via Business Wire
Trillions In Biotech Stock Gains Trace Back To This Financier
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.